OBJECTIVES: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first validated patient-completed measure for assessing outcome in Pulmonary Hypertension (PH). It consists of separate scales assessing Overall Symptoms, Energy Level, Breathlessness, Mood, Physical Functioning and Quality of Life (QoL). This study compares the relative performance of the CAMPHOR with that of generic (Nottingham Health Profile (NHP) and EQ-5D) outcome assessments in PH. METHODS: PH patients completed the instruments in a postal survey. Instruments were compared in terms of end effects, association with clinical indicators (Six Minute Walk Test (6MWT) and New York Heart Association class (NYHA)) and ability to discriminate between patients on the basis of symptom severity and perceived general health. RESULTS: In total, 91 patients participated (mean (SD) age: 52.6 (16.0), 64% female, mean (SD) duration of PH: 4.8 (6.0) years). End effects were slight in the CAMPHOR (Energy scale = 10.1% floor/11.2% ceiling; Mood 19.3% floor) but substantial in the NHP. NHP floor effects ranged from 54.9% (Pain) to 11.9% (Physical Mobility) and ceiling effects from 32.5% (Energy) to 0.0% (Pain and Social). NYHA correlations with the NHP ranged from 0.59 (Physical Mobility) to 0.20 (Pain) and with the CAMPHOR from 0.60 (Functioning) to 0.47 (Overall Symptoms). 6MWT distance correlated 0.71 with CAMPHOR Functioning. All CAMPHOR, NHP (except Sleep) and EQ-5D scales discriminated between patients based on perceived general health (p < .01). The scales also distinguished between patients according to symptom severity (p < .01). All CAMPHOR scales (except Mood) distinguished between NYHA classifications (p ≤ .001). Of the generic measures only the NHP Energy and Physical Mobility scales discriminated according to NYHA. CONCLUSIONS: The CAMPHOR had fewer end effects, showed closer association with clinical indicators and greater sensitivity to NYHA class than the generic measures and is therefore recommended for assessing outcome in PH.